Amphastar Pharmaceuticals Q1 2026 Financial Results: Revenue and EPS Miss Estimates
Amphastar Pharmaceuticals, Inc. Reported a challenging first quarter for 2026, as the company faced significant headwinds in earnings and revenue. Despite successful product launches and growth in specific consumer segments, the company’s bottom line fell short of market expectations, highlighting ongoing pricing pressures and shifts in its product portfolio.
Financial Performance Overview
The company’s most recent quarterly results revealed a mismatch between performance and analyst projections. Amphastar reported flat revenue of $171.2 million, representing a 1.1% miss compared to expectations. More significantly, the company reported a non-GAAP earnings per share (EPS) of $0.42, which constitutes a 40.5% shortfall from estimated figures.
While the top-line revenue remained relatively stable, the discrepancy in EPS suggests that increased costs or pricing dynamics impacted profitability more heavily than anticipated during this period.
Product Performance and Market Dynamics
Amphastar’s quarterly performance was characterized by a mix of declining legacy revenue and successful new product entries. The company’s performance was driven by a return to growth from recent launches, which helped offset some of the competitive pressures seen in older product lines.
BAQSIMI Revenue Trends
One of the primary drivers of the quarterly results was the performance of BAQSIMI. Although unit volume for the product increased by 8%, total revenue for BAQSIMI declined by 15%. This divergence is largely attributed to higher rebates and potential duplicate 340B pharmacy discounts, which have pressured the product’s net pricing.
Growth in OTC and New Launches
Conversely, other segments showed positive momentum:
- Primatene MIST: This product maintained strong momentum with a 6.5% increase in store-level sales, reflecting sustained brand strength and consumer adoption within the over-the-counter (OTC) market.
- AMP-007 (Ipratropium Bromide): The company successfully launched AMP-007 in April. It currently holds a unique position as the first and only generic inhalation product of its kind on the market.
Strategic Initiatives and Margin Management
To combat margin compression and the pricing challenges faced by products like BAQSIMI, management is implementing several strategic adjustments. The company is engaging third-party consultants to validate rebate claims and has announced a 3% list price increase for BAQSIMI to help stabilize revenue.
Amphastar is moving toward portfolio optimization. Starting in July, the company expects to begin withdrawing BAQSIMI from several non-core international markets. This move is designed to focus resources on top-selling markets and more profitable regions while maintaining its presence in most foreign territories.
Future Outlook and Pipeline Development
Looking ahead, Amphastar has maintained its full-year corporate sales guidance, projecting mid-single-digit to high single-digit unit growth. While BAQSIMI revenue expectations for 2026 have been revised to be either flat or seeing low single-digit growth, the company’s long-term pipeline remains a key focus for investors.
The company’s development programs for insulin aspart biosimilars (AMP-004) and GLP-1 ANDA programs remain on track. These complex biosimilars are currently slated for planned commercial launches in 2027, representing a significant component of the company’s future growth strategy.
Key Takeaways
- Earnings Miss: Non-GAAP EPS of $0.42 missed estimates by over 40%.
- Revenue Stability: Revenue reached $171.2 million, a slight 1.1% miss.
- BAQSIMI Pressure: Revenue fell 15% due to rebates, despite an 8% rise in volume.
- New Market Entry: The April launch of AMP-007 provides a unique competitive advantage in the inhalation market.
- Future Pipeline: Insulin and GLP-1 programs are expected to launch in 2027.
Frequently Asked Questions
Why did BAQSIMI revenue decline despite higher sales volume?
The decline in revenue, despite an 8% increase in unit volume, was primarily driven by higher rebates and potential duplicate 340B pharmacy discounts, which reduced the net revenue per unit.
What is management doing to address margin compression?
Management is addressing margin compression by implementing a 3% list price increase for BAQSIMI and utilizing third-party consultants to validate rebate claims.
When are the new insulin and GLP-1 products expected to launch?
The insulin aspart biosimilar (AMP-004) and GLP-1 ANDA programs are currently on track for commercial launches in 2027.
Worth a look